Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2086-2095

  Simpkins, Alexis N ^a   Rudic, R Daniel ^a   Schreihofer, Derek A ^a   Roy, Sid ^a   Manhiani, Marlina ^a   Tsai, Hsing Ju ^b   Hammock, Bruce D ^b   Imig, John D ^a,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ENALAPRIL; ENZYME INHIBITOR; EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HYPERTENSION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 67049119782     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080544     Document Type: Article

References (54)

1. Imig JD: Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 2006, 24:169-188 (Pubitemid 46696923)
2. Fleming I: Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008, 18:20-25
3. Liu M, Alkayed NJ: Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metab 2005, 25:939-948 (Pubitemid 41061709)
4. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC: Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006, 99:442-450 (Pubitemid 44253701)
5. Spector AA, Fang X, Snyder GD, Weintraub NL: Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004, 43:55-90 (Pubitemid 37433867)
6. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E: The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005, 14:2829-2837 (Pubitemid 41418788)
7. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF: Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003, 64:482-490 (Pubitemid 36910013)
8. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD: An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005, 46:842-848 (Pubitemid 44378259)
9. Coyle P: Dorsal cerebral collaterals of stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar Kyoto rats (WKY). Anat Rec 1987, 218:40-44 (Pubitemid 17078693)
10. Coyle P, Jokelainen PT: Differential outcome to middle cerebral artery occlusion in spontaneously hypertensive stroke-prone rats (SHRSP) and Wistar Kyoto (WKY) rats. Stroke 1983, 14:605-611
11. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ: Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007, 27:1931-1940 (Pubitemid 350129162)
12. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD: Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007, 50:3825-3840 (Pubitemid 47292046)
13. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD: The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007, 50:225-237 (Pubitemid 47428969)
14. Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91 (Pubitemid 19040218)
15. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476 (Pubitemid 16085691)
16. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M: Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688 (Pubitemid 33055324)
17. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10:290-293 (Pubitemid 20096202)
18. Zhang W, Kooper D, Alkayed NJ: Soluble epoxide hydrolase gene deletion is associated with increased cbf and reduced stroke damage. Stroke 2006, 37:683
19. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD: Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008, 51:352-359 (Pubitemid 351159950)
20. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121 (Pubitemid 32397092)
21. Newman JW, Denton DL, Morisseau C, Koger CS, Wheelock CE, Hinton DE, Hammock BD: Evaluation of fish models of soluble epoxide hydrolase inhibition. Environ Health Perspect 2001, 109:61-66 (Pubitemid 32118027)
22. Wolf NM, Morisseau C, Jones PD, Hock B, Hammock BD: Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal Biochem 2006, 355:71-80 (Pubitemid 44041405)
23. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JY, Hammock BD, Spector AA: Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 2005, 314:260-270 (Pubitemid 41058263)
24. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL: Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 2006, 26:2462-2468 (Pubitemid 44607466)
25. New DI, Chesser AM, Thuraisingham RC, Yaqoob MM: Structural remodeling of resistance arteries in uremic hypertension. Kidney Int 2004, 65:1818-1825 (Pubitemid 38591031)
26. Izzard AS, Graham D, Burnham MP, Heerkens EH, Dominiczak AF, Heagerty AM: Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. Am J Physiol 2003, 285:H1489-H1494 (Pubitemid 37169502)
27. Jesmin S, Togashi H, Mowa CN, Ueno K, Yamaguchi T, Shibayama A, Miyauchi T, Sakuma I, Yoshioka M: Characterization of regional cerebral blood flow and expression of angiogenic growth factors in the frontal cortex of juvenile male SHRSP and SHR. Brain Res 2004, 1030:172-182 (Pubitemid 39574950)
28. Jesmin S, Togashi H, Sakuma I, Mowa CN, Ueno K, Yamaguchi T, Yoshioka M, Kitabatake A: Gonadal hormones and frontocortical expression of vascular endothelial growth factor in male stroke-prone, spontaneously hypertensive rats, a model for attention-deficit/hyperactivity disorder. Endocrinology 2004, 145:4330-4343 (Pubitemid 39120583)
29. Watanabe T, Schulz D, Morisseau C, Hammock BD: High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta 2006, 559:37-44 (Pubitemid 43184285)
30. Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M: Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol 2006, 291:H517-H531 (Pubitemid 44175056)
31. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, Lu ZY, Wang DW, Zeldin DC: Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol 2007, 293:H142-H151
32. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 2005, 65:4707-4715 (Pubitemid 40740807)
33. Chen JK, Capdevila J, Harris RC: Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 2001, 21:6322-6331 (Pubitemid 34263530)
34. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, Zeldin DC: Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001, 60:310-320 (Pubitemid 32678296)
35. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997, 277:693-696 (Pubitemid 27373916)
36. Kim IJ, Lee KW, Park BY, Lee JK, Park J, Choi IY, Eom SJ, Chang TS, Kim MJ, Yeom YI, Chang SK, Lee YD, Choi EJ, Han PL: Molecular cloning of multiple splicing variants of JIP-1 preferentially expressed in brain. J Neurochem 1999, 72:1335-1343 (Pubitemid 29140801)
37. Becker AJ, Gillardon F, Blumcke I, Langendorfer D, Beck H, Wiestler OD: Differential regulation of apoptosis-related genes in resistant and vulnerable subfields of the rat epileptic hippocampus. Brain Res Mol Brain Res 1999, 67:172-176 (Pubitemid 29170080)
38. Harding TC, Xue L, Bienemann A, Haywood D, Dickens M, Tolkovsky AM, Uney JB: Inhibition of JNK by overexpression of the JNL binding domain of JIP-1 prevents apoptosis in sympathetic neurons. J Biol Chem 2001, 276:4531-4534 (Pubitemid 37371330)
39. Segura MF, Sole C, Pascual M, Moubarak RS, Perez-Garcia MJ, Gozzelino R, Iglesias V, Badiola N, Bayascas JR, Llecha N, Rodriguez- Alvarez J, Soriano E, Yuste VJ, Comella JX: The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis. J Neurosci 2007, 27:11228-11241 (Pubitemid 47628520)
40. Sole C, Dolcet X, Segura MF, Gutierrez H, Diaz-Meco MT, Gozzelino R, Sanchis D, Bayascas JR, Gallego C, Moscat J, Davies AM, Comella JX: The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-kappa B signaling. J Cell Biol 2004, 167:479-492 (Pubitemid 39489056)
41. Hainsworth AH, Bermpohl D, Webb TE, Darwish R, Fiskum G, Qiu J, McCarthy D, Moskowitz MA, Whalen MJ: Expression of cellular FLICE inhibitory proteins (cFLIP) in normal and traumatic murine and human cerebral cortex. J Cereb Blood Flow Metab 2005, 25:1030-1040 (Pubitemid 41061718)
42. Matsumori Y, Northington FJ, Hong SM, Kayama T, Sheldon RA, Vexler ZS, Ferriero DM, Weinstein PR, Liu J: Reduction of caspase-8 and -9 cleavage is associated with increased c-FLIP and increased binding of Apaf-1 and Hsp70 after neonatal hypoxic/ischemic injury in mice overexpressing Hsp70. Stroke 2006, 37:507-512 (Pubitemid 43732015)
43. Mori M, Burgess DL, Gefrides LA, Foreman PJ, Opferman JT, Korsmeyer SJ, Cavalheiro EA, Naffah-Mazzacoratti MG, Noebels JL: Expression of apoptosis inhibitor protein Mcl1 linked to neuroprotection in CNS neurons. Cell Death Differ 2004, 11:1223-1233 (Pubitemid 39529965)
44. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2002, 99:2222-2227 (Pubitemid 34169042)
45. Nieves D, Moreno JJ: Epoxyeicosatrienoic acids induce growth inhibition and calpain/caspase-12 dependent apoptosis in PDGF cultured 3T6 fibroblast. Apoptosis 2007, 12:1979-1988 (Pubitemid 47498231)
46. Zhang C, Harder DR: Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic Acid. Stroke 2002, 33:2957-2964 (Pubitemid 35462872)
47. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ: Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 2007, 27:4642-4649 (Pubitemid 46663588)
48. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K: Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9:699-706 (Pubitemid 32772892)
49. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe Jr RT, McKee DD, Moore JT, Willson TM: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 2001, 98:13919-13924 (Pubitemid 33115999)
50. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, Debarber AE, Koop DR, Alkayed NJ. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 2008, 39:2073-2078
51. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA: The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006, 37:345-350 (Pubitemid 43731985)
52. Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh III EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41
53. Han SW, Kim SH, Lee JY, Chu CK, Yang JH, Shin HY, Nam HS, Lee BI, Heo JH: A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol 2007, 57:96-102 (Pubitemid 46256989)
54. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M: Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 2008, 39:1593-1596